Your session is about to expire
← Back to Search
Antisense Oligonucleotide
IONIS-AGT-LRx for Heart Failure (ASTRAAS-HF Trial)
Phase 2
Waitlist Available
Research Sponsored by Ionis Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 169
Awards & highlights
Summary
This trial tests a weekly under-the-skin shot called IONIS-AGT-LRX for people with a type of heart failure where the heart doesn't pump well. The treatment aims to lower specific proteins in the blood that affect heart function and fluid balance. The study will last several months and include up to 72 participants.
Eligible Conditions
- Heart Failure
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 169
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 169
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percent Change in Plasma AGT Concentration From Baseline to Study Day 85
Secondary outcome measures
Absolute Level of NT-proBNP
Absolute Level of Plasma AGT
Change in NT-proBNP From Baseline to Each Scheduled, Post-Baseline Visit
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: IONIS-AGT-LRxExperimental Treatment1 Intervention
IONIS-AGT-LRX by subcutaneous injection once-weekly
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by subcutaneous injection once-weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IONIS-AGT-LRx
2021
Completed Phase 2
~240
Find a Location
Who is running the clinical trial?
Ionis Pharmaceuticals, Inc.Lead Sponsor
148 Previous Clinical Trials
15,425 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger